Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $4.0 million.

  • Caribou Biosciences' Current Deferred Revenue fell 4136.66% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 4136.66%. This contributed to the annual value of $6.4 million for FY2024, which is 2796.96% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Current Deferred Revenue is $4.0 million, which was down 4136.66% from $4.6 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Current Deferred Revenue high stood at $31.1 million for Q2 2023, and its period low was $4.0 million during Q3 2025.
  • Moreover, its 5-year median value for Current Deferred Revenue was $8.8 million (2021), whereas its average is $13.6 million.
  • In the last 5 years, Caribou Biosciences' Current Deferred Revenue surged by 1899006.21% in 2021 and then plummeted by 7611.66% in 2024.
  • Over the past 5 years, Caribou Biosciences' Current Deferred Revenue (Quarter) stood at $30.7 million in 2021, then fell by 15.76% to $25.9 million in 2022, then crashed by 65.44% to $8.9 million in 2023, then fell by 27.97% to $6.4 million in 2024, then plummeted by 38.36% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q3 2025, $4.6 million for Q2 2025, and $5.4 million during Q1 2025.